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molecular and cytogenetic predictors of survival and treatment
outcome
This article has been corrected since Online Publication and an erratum has also been published
MM Patnaik1, EA Wassie1, E Padron2, F Onida3, R Itzykson4, TL Lasho1, O Kosmider5,6, CM Finke1, CA Hanson7, RP Ketterling8,
R Komrokji2, A Tefferi1 and E Solary9,10
In patients with chronic myelomonocytic leukemia (CMML), age465 years is an adverse prognostic factor. Our objective in the
current study was to examine risk factors for survival and treatment outcome in 261 ‘young’ adults with CMML, as deﬁned by age
⩽ 65 years. In multivariable analysis, lower HB (P= 0.01), higher circulating blast % (P= 0.002), ASXL1 (P= 0.0007) and SRSF2
mutations (P= 0.008) and Mayo-French cytogenetic stratiﬁcation (P= 0.04) negatively impacted survival. Similarly, leukemia-free
survival was independently affected by higher circulating blast % (Po0.0001), higher bone marrow blast % (P= 0.0007) and the
presence of circulating immature myeloid cells (P= 0.0002). Seventy-ﬁve (29%) patients received hypomethylating agents (HMA),
with the median number of cycles being 5, and the median duration of therapy being 5 months. The over-all response rate was
40% for azacitidine and 30% for decitabine. Fifty-three (24%) patients underwent an allogeneic hematopoietic stem cell transplant
(AHSCT), with a response rate of 56% and a non-relapse mortality of 19%. Survival in young adults with CMML, although higher
than in older patients, is poor and even worse in the presence of ASXL1 and SRSF2 mutations. Treatment outcome was more
impressive with AHSCT than with HMA and neither was inﬂuenced by ASXL1/SRSF2 mutations or karyotype.
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INTRODUCTION
Chronic myelomonocytic leukemia (CMML) is a clonal hemato-
poietic stem cell disorder, with overlapping features of myelodys-
plastic syndromes and myeloproliferative neoplasms, and is
associated with an inherent risk of transformation to acute
myeloid leukemia.1 The median age of presentation ranges
between 71–74 years, with a male predilection.2–4 In fact, age
465 years has been shown to be an adverse prognosticator,
impacting over-all survival (OS).2 There, however, are a fair number
of patients that present earlier than the seventh decade of life. In
two large studies the age ranges of disease presentation were;
20–93 years for the Mayo Clinic study,3 and 40–91 years for the
Groupe Francophone des Myelodysplasies (GFM) study.2
Cytogenetic abnormalities are seen in 20–30% of patients,
whereas gene mutations, especially those causing epigenetic
dysregulation (TET2, IHD1, IDH2 and DNMT3A), abnormalities in
chromatin dynamics (ASXL1 and EZH2), affecting the spliceosome
component machinery (SRSF2, SF3B1 and U2AF1) and the signal
transduction pathways (JAK2, KRAS, NRAS and CBL) can be seen in
every patient (1, 3, 5 and our unpublished data). Of these,
mutations involving TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%) and
the RAS pathway (~30%) are most common, with only frame-shift
and non-sense mutations of ASXL1 independently impacting OS.2,3
Contemporary prognostic models, incorporating molecular
information, include the Mayo Molecular Model (MMM) and the
GFM model. The MMM includes; hemoglobin (HB)o10 gm/dl,
absolute monocyte count (AMC) 410 × 10(9)/l, circulating imma-
ture myeloid cells (IMCs), platelet counto100× 10(9)/l and the
presence of ASXL1 mutations, risk stratifying patients into four
categories: low, intermediate-1/2 and high risk, with median OS of
97 months, 59 months, 37 months and 16 months, respectively.3
The GFM includes; age 465 years, anemia (HBo11 gm/dl in
males and 10 gm/dl in females), white blood count (WBC)
415 × 10(9)/l, plateletso100 × 10(9)/l and ASXL1 mutations, risk
stratifying patients into three categories; low, intermediate and
high risk, with median OS of not reached, 38.5 months and
14.4 months, respectively.2 In addition, recently, the Mayo-French
cytogenetic risk stratiﬁcation system was developed, stratifying
patients into three groups; high (complex and monosomal
karyotype), intermediate (all karyotypes not belonging to high
and low risk groups) and low risk (normal, − Y and der(3q)), with
median OS of 3 months, 20 months and 41 months, respectively.5
In this study, advanced age was signiﬁcantly associated with the
presence of an abnormal karyotype (P= 0.03).
Treatment options for CMML are limited, and include therapy
with hypomethylating agents (HMA) or allogeneic hematopoietic
stem cell transplant (AHSCT). There is no phase III data supporting
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Table 1. Clinical and laboratory features and subsequent events in 261 ‘young’ (age⩽ 65 years) adults with WHO-deﬁned chronic myelomonocytic
leukemia, stratiﬁed by allogenic stem cell transplant status
Variable All patients
n= 261
Transplanted
patents n= 53 (24%)
Non-transplant
patients n=167 (76%)
P-value
Age in years; median (range) 59 (18–65) 52 (18–65) 60 (20–65) o0.0001
Males; n (%) 192 (73%) 32 (60%) 128 (77%) 0.02
Hemoglobin g/dl; median (range) 11.0 (4.2–17.7) 10.1 (4.2–15.5) 10.9 (4.9–17.7) 0.006
WBC× 109/l; median (range) 12.4 (1.8–180.0) 14.8 (2.5–133.0) 11.4 (1.8–180) 0.08
ANC× 109/l; median (range) 5.7 (0.2–151) 5.9 (0.3–92.6) 5.3 (0.2–151) 0.5
AMC× 109/l; median (range) 2.6 (0.3–62.8) 3.1 (0.6–62.8) 2.6 (0.3–44) 0.3
ALC× 109/l; median (range) 2.1 (0–12.5) 2.6 (0.3–12.5) 2.0 (0–8.1) 0.01
Platelets× 109/l; median (range) 99 (6–1427) 72 (6–1064) 107 (10–1427) 0.1
PB blast %; median (range) 0 (0–16) 0 (0–16) 0 (0–16) 0.1
BM blast %; median (range) 4 (0–18) 6 (0–18) 4 (0–16) 0.001
Circulating immature myeloid cells; n (%) ‘N’ evaluable = 258 141 (55%) 29 (55%) 86 (52%) 0.8
WHO morphological subtype; n (%)
CMML-1 219 (84%) 36 (68%) 146 (87%) 0.001
CMML-2 42 (16%) 17 (32%) 21 (13%) —
ASXL1 mutations; ‘N’ evaluable = 174 58 (33%) 7 (28%) 37 (34%) 0.6
SETBP1 mutations; ‘N’ evaluable = 164; n (%) 7 (4%) 0 (0%) 4 (4%) 0.3
Spliceosome component mutations;
SF3B1 ‘N’ evaluable = 113 9 (8%) 1 (6%) 5 (9%) 0.7
SRSF2 ‘N’ evaluable = 161 72 (45%) 8 (33%) 47 (48%) 0.2
U2AF1 ‘N’ evaluable = 111 5 (4%) 1 (6%) 3 (5%) 0.9
Spanish cytogenetic risk stratiﬁcation; ‘N’ evaluable = 246 n (%)
Low 196 (80%) 40 (75%) 124 (78%) 0.7
Intermediate 28 (11%) 6 (11%) 20 (13%) —
High 22 (9%) 7 (13%) 15 (9%) —
Mayo-French cytogenetic risk stratiﬁcation; ‘N’ evaluable = 246, n (%)
Low 200 (81%) 40 (75%) 126 (79%) 0.6
Intermediate 39 (16%) 12 (23%) 27 (17%) —
High 7 (3%) 1 (2%) 6 (4%) —
MD Anderson prognostic risk categories; n (%) ‘N’ evaluable = 254
Low 111 (44%) 17 (33%) 74 (46%) 0.02
Intermediate-1 51 (20%) 17 (33%) 50 (31%) —
Intermediate-2 85 (33%) 13 (25%) 35 (67%) —
High 7 (3%) 5 (10%) 2 (1%) —
Mayo Model prognostic risk categories; n (%) ‘N’ evaluable = 259
Low 65 (25%) 9 (17%) 48 (29%) 0.1
Intermediate 92 (36%) 18 (34%) 58 (35%) —
High 102 (39%) 26 (49%) 59 (36%) —
Mayo Molecular Model ‘N’ evaluable = 171
Low 20 (12%) 1 (4%) 13 (12%) —
Intermediate-1 46 (26%) 5 (20%) 31 (29%) 0.1
Intermediate-2 61 (36%) 8 (32%) 39 (37%) —
High 44 (26%) 11 (44%) 23 (22%) —
GFM prognostic risk categories; n (%) ‘N’ evaluable = 171
Low 106 (62%) 12 (48%) 68 (64%) 0.2
Intermediate 61 (36%) 13 (52%) 35 (33%) —
High 4 (2%) 0 (0%) 3 (3%) —
— — — —
Leukemic transformations; n (%) ‘N’ evaluable = 258 72 (28%) — — —
Before transplant — 19 (36%) 41 (24%) —
After transplant — 5 (9%) — —
Deaths; n (%) 126 (48%) 25 (47%) 92 (55%) 0.3
Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; ASXL1, additional sex combs 1 gene; BM,
bone marrow; CMML, chronic myelomonocytic leukemia; GFM, Groupe Francais des Myelodsyplasies; PB, peripheral blood; SF3B1, splicing factor 3B, subunit 1;
SRSF2, serine/arginine-rich splicing factor 2; U2AF1, U2 small nuclear RNA auxiliary factor 1; WBC, white blood cell count; WHO, World Health Organization.
Mayo-French cytogenetic risk stratiﬁcation: Low risk, normal karyotype, −Y and sole der (3q); high risk, complex and monosomal karyotype; intermediate all
other karyotype abnormalities; Spanish cytogenetic risk stratiﬁcation: Low risk, −Y and normal karyotype; high risk, +8, − chromosome 7 abnormalities and
complex karyotype: intermediate risk, all other abnormalities. Bold entries signify statistically signiﬁcant P-values (i.e. Po0.05).
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the use of HMA in CMML, however, several phase II studies have
been completed with overall response rates ranging from 25–70%,
and median OS ranging from 12 to 37 months.6–12 Unfortunately,
the retrospective nature of the vast majority of the studies
along with the lack of a comparator arm makes it difﬁcult to draw
cross-study conclusions. While AHSCT is a curative strategy, it is
currently not widely utilized given issues with donor eligibility
(advanced age), limited donor pools and the risk of complications
such as graft rejection, acute and chronic graft versus host disease
(GVHD) and non-relapse mortality (NRM). Most AHSCT studies
have been retrospective, with a mix of myeloablative (MA) and
reduced intensity conditioning (RIC) regimens, with NRM ranging
from 12–40% and relapse rates ranging from 25–40%, making it
very difﬁcult to draw concrete conclusions.1,13,14
While there is a modest pool of clinical, prognostic and
therapeutic information on patients with CMML, not much is
known about those that present prior to the seventh decade of
life. In a large study on primary myeloﬁbrosis (n= 1000), patients
with age o60 years (n= 299) had a dynamic international
prognostic scoring system (DIPSS-plus) stratiﬁed survival that
was better than that of the overall cohort, with median OS of 20.0
years, 14.3 years, 5.3 years and 1.7 years for low, intermediate-1/2
and high risk disease, respectively, compared with 15.6 years, 5.6
years, 2.5 years and 1.4 years for the entire cohort.15 Similarly, the
clinical characteristics, karyotypic and molecular abnormalities,
and outcomes of ‘young’ adults with CMML are not well-deﬁned.
These patients are more likely to be offered therapies impacting
survival, such as, HMA and AHSCT. Given that the median age of
presentation for CMML is in the seventh decade of life and since
age465 years was found to be an adverse prognosticator, for the
purposes of this study, we deﬁned ‘young’ CMML as age ⩽ 65
years. We carried out this international collaborative effort to
deﬁne the molecular and cytogenetic predictors of survival and
treatment outcomes in ‘young’ adults with CMML.
MATERIALS AND METHODS
The current study was an international collaborative effort between the
Mayo Clinic, MN, USA the Mofﬁtt Cancer Center, FL, USA, the GFM and
the University of Milan in Italy, and was duly approved by the respective
institutional review boards. Study eligibility criteria included availability of
peripheral blood (PB) smear, bone marrow (BM) cytology or histology, and
cytogenetic information at the time of referral to the respective
institutions. As mentioned above, ‘young’ CMML was deﬁned as age
⩽ 65 years. The diagnoses of CMML, including sub-classiﬁcation into
CMML-1 or CMML-2 and documentation regarding the presence or
absence of ring sideroblasts and leukemic transformation (LT) were
according to the 2008 WHO (World Health Organization) criteria.16 All
complete blood count differentials and PB smears were evaluated for
presence of circulating IMCs, deﬁned by the presence of any of the
following cells in circulation; myeloblasts, myelocytes, metamyelocytes and
promyelocytes.17
At the time of CMML diagnosis, DNA from BM or PB, was extracted using
conventional methods. JAK2, ASXL1, SF3B1, SRSF2, U2AF1 and SETBP1
mutation analysis was performed according to previously published
methods.2,18–21 Based on prior observations, only frame-shift and non-
sense ASXL1 mutations were considered bona ﬁde mutations.3,4 In the
French CMML cohort a sub-group of patients did have DNA analysis for
TET2 and RAS mutations, while these were not done on the remainder.2
Karyotype risk designation and CMML risk stratiﬁcation were according
to the Spanish cytogenetic risk stratiﬁcation system,22 the Mayo-French
cytogenetic classiﬁcation,5 the MD Anderson prognostic system
(MDAPS),17 the GFM model,2 the Mayo Prognostic Model4 and the
MMM.3 In the analysis of prognostic factors, variables included were:
gender, HB, WBC, absolute neutrophil count, AMC, absolute lymphocyte
count, platelet count, PB and BM blasts, circulating IMC, BM cellularity,
WHO morphological subcategories (CMML-1 versus CMML-2), karyotype
groups based on the Spanish cytogenetic risk stratiﬁcation system and the
Mayo-French cytogenetic classiﬁcation, MDAPS, Mayo prognostic model,
GFM model, MMM, ASXL1 mutations, spliceosome component mutations
(SF3B1, SRSF2 and U2AF1) and SETBP1 mutations.
Treatment data collected included: best supportive care options (blood
transfusions, hydroxyurea and erythropoiesis stimulating agents), the use
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Median OS=25 months
P = 0.0003
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P = 0.009
P < 0.0001
Figure 1. Overall survival of ‘young’ adults with chronic myelomonocytic leukemia stratiﬁed by contemporary prognostic models. (a) Overall
survival of 171 ‘young’ adults with chronic myelomonocytic leukemia stratiﬁed by the Molecular Mayo Model. (b) Overall survival of
171 ‘young’ adults with chronic myelomonocytic leukemia stratiﬁed by the GFM model. (c) Overall survival of 254 ‘young’ adults with chronic
myelomonocytic leukemia stratiﬁed by the MD Anderson prognostic model. (d) Overall survival of 257 ‘young’ adults with chronic
myelomonocytic leukemia stratiﬁed by the Mayo prognostic model.
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of HMA (5-Azacitidine (AZA) and/or decitabine (DAC), either as single agents
or in the setting of a clinic trial) and the use of AHSCT. Responses to HMA
were graded according to the International Working Group (IWG) response
criteria.23 For AHSCT, data collected included: donor source (matched related
donor, matched unrelated donor (MUD), double umbilical cord blood units
or haploidentical donors), graft type (PB versus BM), conditioning regimen
(MA versus RIC) and transplant outcomes such as engraftment rates, acute
and chronic GVHD, relapse free survival, NRM and OS.
All statistical analyses considered clinical and laboratory parameters
obtained at the time of referral to the participating institutions, which in
most instances coincided with the time of BM aspiration or biopsy and
study sample collection. Differences in the distribution of continuous
variables between categories were analyzed by either Mann–Whitney (for
comparison of two groups) or Kruskal–Wallis (comparison of three or more
groups) tests. Patient groups with nominal variables were compared by
χ2-test. Overall survival was calculated from the date of ﬁrst referral to the
date of death (uncensored) or last contact (censored). Leukemia-free
survival (LFS) was calculated from the date of ﬁrst referral to date of LT
(uncensored) or death/last contact (censored). Overall and LFS curves were
prepared by the Kaplan–Meier method and compared by the log-rank test.
Cox proportional hazard regression model was used for multivariable
analysis. P-values o0.05 were considered signiﬁcant. The Stat View (SAS
Institute, Cary, NC, USA) statistical package was used for all calculations.
RESULTS
Two hundred and sixty-one patients with WHO-deﬁned CMML were
included in the current international study: 105 (40%) were from
the GFM cohort, 86 (33%) from Mayo Clinic Minnesota, 47 (18%)
from the Mofﬁtt Cancer Center Florida and 23 (9%) from the
University of Milan. There were no statistically signiﬁcant demo-
graphic, clinical or laboratory differences between patients from the
four participating centers. Two hundred and nineteen (84%)
patients had CMML-1 and 42 (16%) had CMML-2, with median
OS of 59 months and 24 months, respectively. The median age of
the cohort was 59 years (range, 18–65 years) and 73% (n=192)
were males. Table 1 outlines the presenting clinical and laboratory
features and subsequent events in the 261 study patients with
CMML, stratiﬁed by their AHSCT status. At a median follow-up of
26 months, 126 (48%) deaths and 72 (28%) LTs were documented.
Of 220 evaluable patients, 53 (24%) did undergo AHSCT and in this
group at last follow-up 8 (19%) deaths were documented.
Cytogenetic information was available in 246 (94%) patients; 60
(23%) displayed an abnormal karyotype and the Mayo-French
cytogenetic risk designations included 200 (81%) low, 39 (16%)
intermediate and 7 (3%) high risk. The common cytogenetic
abnormalities included: − 7(18%), +8 (16%), − Y (14%), der(3q)
(13%) and 20q-(9%). Forty-ﬁve (80%) of the 60 patients had a sole
abnormality, while 4 (7%) had two, 7 (13%) had a complex
karyotype and 6 (11%) had a monosomal karyotype.
Mutational frequencies were 45% (72/161) for SRSF2, 33%
(58/174) for ASXL1, 8% (9/113) for SF3B1, 4% (7/164) for SETBP1
and 4% (5/111) for U2AF1. The most common ASXL1 mutation was
the c.1934dupG; p.G646WfsX12 variant (40%), followed by the
1900_1922_ del (11%). The most common SRSF2 mutations were
P95H (33%) and P95L (33%), while K700E (90%) was the most
common SF3B1 mutation. In the French CMML cohort, of the 53
evaluable patients 29(53%) had TET2 mutations, while of the 59
evaluable patients 13 (22%) had RAS mutations (NRAS-10 and
KRAS-3). The distribution according to the four studied risk
stratiﬁcation algorithms is shown in Figure 1. For example, the
distribution according to the MMM was: 20 (12%) low, 46 (26%)
intermediate-1, 61 (36%) intermediate-2 and 44 (26%) high risk.
Survival
Figure 2a demonstrates the OS of 261 ‘young’ adults with CMML.
With a median follow-up of 54.5 months, overall survival was 84% at
1 year, 45% at 5 years, and 26% at 10 years, with a median survival of
55 months. Themedian OS for CMML-1 and CMML-2 were 59months
and 24 months, respectively (Figure 2b). In an univariate OS analysis,
after censoring for AHSCT lower HB (Po0.0001), higher WBC
(P=0.0002), higher absolute neutrophil count (P=0.001), higher AMC
(P=0.0004), higher circulating blast % (Po0.0001), higher BM blast
% (P=0.02), presence of circulating IMC (Po0.0001), ASXL1
mutations (P=0.003), SRSF2 mutations (P=0.04), the Mayo-French
cytogenetic risk stratiﬁcation (Po0.0001) and the Spanish cytoge-
netic risk stratiﬁcation system (P=0.0002) predicted shortened
survival (Table 2). In multivariable analysis, lower HB (P=0.01), higher
circulating blast % (P=0.002), ASXL1 mutations (P=0.0007), SRSF2
mutations (P=0.008) and the Mayo-French cytogenetic risk stratiﬁca-
tion system (P=0.04) retained their negative prognostic impact.
Interestingly, without censoring for AHSCT, on a multivariable
analysis OS was independently affected by lower HB (P=0.01), lower
platelets (P=0.03), higher circulating blast % (P=0.001), SRSF2
mutations (P=0.04) and the high risk stratiﬁcation of the Mayo-
French cytogenetic stratiﬁcation (P=0.02; Table 2). SETBP1 mutations
had no impact on OS.
Similarly, in a univariate analysis for LFS lower HB (Po0.0001),
higher AMC (P=0.01), higher circulating blast% (Po0.0001), higher
BM blast % (Po0.0001), presence of circulating IMC (Po0.0001),
the Mayo-French cytogenetic risk stratiﬁcation (Po0.0001) and the
Spanish cytogenetic risk stratiﬁcation (Po0.0001) predicted
shortened survival (Table 2). In multivariable analysis, LFS was
independently affected by higher circulating blast % (Po0.0001),
higher BM blast % (P=0.0007) and the presence of circulating IMC
Overall survival of 261 “young” adults with
chronic myelomonocytic leukemia
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Figure 2. (a) Overall survival of 261 ‘young’ adults with chronic
myelomonocytic leukemia. (b) Survival of 261 ‘young’ adults with
chronic myelomonocytic leukemia stratiﬁed by the World health
organization (WHO) morphologic classiﬁcation.
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(P=0.0002). Karyotype risk designation, ASXL1, SETBP1 and SRSF2
mutations had no impact on LFS.
Response to HMAs
Seventy-ﬁve (29%) patients received HMA, of which, 45 (60%)
received 5-AZA, 30 (40%) received DAC and 7 (9%) received both.
Table 3 outlines the treatment characteristics and outcomes of
‘young’ CMML patients that received HMA. In the 5-AZA group,
the median age was 56 years and 78% (n= 35) were male. Thirty-
ﬁve (78%) had CMML-1, while 10 (22%) had CMML-2. Of 20
evaluable patients, 9 (45%) had ASXL1 mutations. The risk
designations according to the MMM were: 3 (16%) high, 7 (37%)
intermediate-2, 8 (42%) intermediate-1 and 1 (5%) low risk
(evaluable n= 19). The median number of cycles was 5 (range,
1–44), median duration of therapy 4.6 months (range, 0.1–32.2),
with 5 (11%) receiving DAC on progression and 20 (39%)
proceeding with AHSCT. The over-all response rate was 40%
(n= 18/45) and included complete response (CR) in 3 (7%), partial
response in 10 (25%) and hematological improvement (HI) in 5
(12%). Of 30 evaluable patients, reasons for 5-AZA discontinuation
included patient choice-1 (3%), 5-AZA intolerance-3 (10%), disease
progression-14 (47%), death-4 (13%) and bridge to AHSCT-8 (27%).
Thirty (40%) patients received DAC; with the median age being
58 years (range, 33–65), with a male predilection (60%) (Table 3).
Twenty-one (70%) had CMML-1, while 9 (30%) had CMML-2. Of 21
evaluable patients, 6 (28%) had ASXL1 mutations and the risk
designations according to the MMM were: 4 (21%) high risk, 7
(37%) intermediate-2, 6 (32%) intermediate-1 and 2 (10%) low risk.
The median number of cycles was 6 (range, 1–30), median
duration of therapy 5 months (range, 0.1–49), with two (7%)
receiving DAC on progression and nine (31%) proceeding with
AHSCT. The over-all response rate was 30% (n= 9/30) and included
CR in 6 (32%), partial response in one (5%) and HI in two (10%). Of
15 evaluable patients, reasons for DAC discontinuation included
disease progression-9 (60%), death-3(20%) and bridge to AHSCT-3
(20%). Neither did ASXL1 (P= 0.4) and SRSF2 (P= 0.7) mutational
status, nor karyotype (P= 0.3 for Mayo-French cytogenetic
stratiﬁcation and 0.5 for the Spanish stratiﬁcation) correlate with
response to HMA. In 53 evaluable patients in the French cohort,
TET2 mutations demonstrated a trend toward predicting HMA
response (P= 0.5), but this did not reach statistical signiﬁcance.
Outcomes of AHSCT
Fifty-three patients (20%) underwent AHSCT. Conditioning regi-
men was reported in 42 patients and included MA in 14 (33%) and
reduced intensity in 28 (67%) (Table 4). Donor source was
documented in 40 patients and included: matched related donor
in 20 (50%; MA-7 and RIC-13), MUD in 13 (32%; MA-4, RIC-9), 9/10
mismatched unrelated donor in 4 (10%; MA-1, RIC-3), double
umbilical cord blood units in 1 (3%; MA-1) and RIC haploidentical
transplants in 2 (8%). In the MA group, the median age was 51
years (range, 27–62), 32 (60%) were males and 36 (68%) had
CMML-1, while the remaining 17 (32%) had CMML-2. In the RIC
group, the median age was 48 years (range, 18–65), 8 (57%) were
males, 21 (75%) had CMML-1, while the remaining 7 (25%) had
CMML-2. Of 25 evaluable patients, 7 (28%) had ASXL1 mutations
(MA-3, RIC-4) and the risk designation according to the MMM was:
high-11 (44%), intermediate-2-5 (20%), intermediate-1-8 (32%)
and low risk-1 (4%). Nineteen patients (47%) developed grade II–IV
acute GVHD, 7 (54%) with a MA regimen and 12 (46%) with RIC,
while 29 (67%) developed chronic GVHD, 8 (57%) with a MA
regimen and 21 (75%) with RIC. Of 43 evaluable patients, 1 (2%)
had primary engraftment failure, 8 died secondary to treatment
related causes (NRM-19%), 10 (25%) had disease relapse and 24
(56%) achieved a CR. Neither did ASXL1 (P= 0.9) and SRSF2 (P= 0.5)
mutational status, nor karyotype (P= 0.3 for Mayo-French cytoge-
netic stratiﬁcation and 0.2 for the Spanish stratiﬁcation) correlate
with response to AHSCT.
Table 2. Univariate and multi-variable analysis of survival and leukemic transformation in 261 ‘young’ adults with chronic myelomonocytic leukemia
Variable Censor survival
univariate
Censor survival
multivariate
Censor
transplant
univariate
Censor transplant
multivariate
Censor leukemic
transformation
univariate
Censor leukemic
transformation
multivariate
Older age 0.99 — 0.89 — 0.1 —
Males 0.5 — 0.8 — 0.5 —
Lower hemoglobin g/dl o0.0001 0.01 o0.0001 0.01 o0.0001 —
Higher WBC× 109/l 0.002 — 0.0002 — 0.2 —
Higher ANC× 109/l 0.005 — 0.001 — 0.7 —
Higher AMC× 109/l) 0.02 — 0.0004 — 0.01 —
Higher ALC× 109/l 0.9 — 0.3 — 0.07 —
Lower platelets× 109/l 0.004 0.03 0.2 — 0.1 —
Higher PB blast % o0.0001 0.001 o0.0001 0.002 o0.0001 o0.0001
Higher BM blast % 0.007 — 0.02 — o0.0001 0.0007
Presence of circulating
immature myeloid cells
0.007 — o0.0001 — o0.0001 0.0002
ASXL1 mutations 0.06 — 0.003 0.007 0.8 —
SETBP1 mutations 0.07 — 0.05 — 0.4 —
SF3B1 0.5 — 0.2 0.7 —
SRSF2 0.03 0.04 0.04 0.008 0.7 —
U2AF1 0.2 — 0.5 — — —
Mayo-French cytogenetic
risk stratiﬁcation
o0.0001 HOLDS for
high risk 0.02
o0.0001 0.04 o0.0001 —
Spanish cytogenetic risk
stratiﬁcation;
o0.0001 — 0.0002 — o0.0001 —
Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; ASXL1, additional sex combs 1 gene; BM,
bone marrow; PB, peripheral blood; SETBP1, SET binding protein 1; SF3B1, splicing factor 3B, subunit 1; SRSF2, serine/arginine-rich splicing factor 2; U2AF1, U2
small nuclear RNA auxiliary factor 1; WBC, white blood cell count. Mayo-French cytogenetic risk stratiﬁcation; Low risk, normal karyotype, − Y and sole der (3q),
High risk, complex and monosomal karyotype, Intermediate all other karyotype abnormalities, Spanish cytogenetic risk stratiﬁcation; Low risk, −Y and normal
karyotype, High risk, +8, − chromosome 7abnormalities and complex karyotype, Intermediate risk, all other abnormalities. Bold entries signify statistically
signiﬁcant P-values (i.e. Po0.05).
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Table 3. Treatment of ‘young’ CMML patients (age⩽ 65) with hypomethylating agents and their outcome stratiﬁed by their allogenic stem cell
transplant status
Variables All n= 75 CMML patients
that underwent
Allogenic transplant
n= 29 (39%)
CMML patients
without transplant
n= 45 (61%)
P-value
1. 5-Azacitidine n (%) 45 (60%) 20 (71%) 25 (56%) —
Age 56 (30–65) 52 (30–63) 59 (44–65) 0.0009
Male (%) 35 (78%) 14 (70%) 21 (84%) 0.3
WHO morphological subtype; n (%)
CMML-1 35 (78%) 16 (80%) 19 (76%) 0.7
CMML-2 10 (22%) 4 (20%) 6 (24%) —
ASXL1 mutated ‘N’ evaluable = 20 9 (45%) 4 (50%) 5 (42%) 0.7
SRSF2 mutated ‘N’ evaluable = 19 9 (47%) 2 (22%) 7 (70%) 0.04
Mayo Molecular Model risk categorization ‘N’ evaluable = 19
Low 1 (5%) 0 (0%) 1 (9%) —
Intermediate-1 8 (42%) 4 (50%) 4 (36%) 0.3
Intermediate-2 7 (37%) 0 (0%) 3 (27%) —
High 3 (16%) 4 (50%) 3 (27%) —
Mayo-French cytogenetic stratiﬁcation ‘N’ evaluable = 74
Low 33 (73%) 14 (70%) 19 (76%) 0.5
Intermediate 11 (24%) 6 (30%) 5 (20%) —
High 1 (2%) 0 (0%) 1 (4%) —
Median cycles (range) 5 (1–44) 4 (2–44) 6 (1–36) 0.3
Median duration of therapy in months (range) 4.6 (0.1–32) 3.8 (0.1–18) 4.6 (0.1–32) 0.6
Best response ‘N’ evaluable = 40
HI 5 (13%) 2 (10%) 3 (14%) 0.4
PR 10 (25%) 6 (32%) 4 (19%) —
CR 3 (7%) 0 (0%) 3 (14%) —
No response 22 (55%) 11 (58%) 7 (33%) —
Reason for discontinuation of therapy ‘N’ evaluable = 30
Patient choice 1 (3%) 0 (0%) 1 (6%) —
Intolerance 3 (10%) 0 (0%) 3 (18%) 0.01
Progression 14 (47%) 7 (47%) 7 (41%) —
Bridge to transplant 8 (27%) 8 (53%) 0 (0%) —
Death 4 (13%) 0 (0%) 4 (23%) —
Second HMA n (%) 5 (11%) 3 (15%) 2 (8%) —
2. Decitabine 30 (40%) 9 (31%) 20 (68%) —
Age 58 (33–65) 57 (43–65) 59 (33–65) 0.7
Male (%) 18 (60%) 3 (37%) 15 (75%) 0.6
WHO morphological subtype; n (%)
CMML-1 21 (70%) 5 (56%) 16 (76%) 0.3
CMML-2 9 (30%) 4 (44%) 5 (24%) —
ASXL1 mutated ‘N’ evaluable = 21 6 (28%) 1 (20%) 5 (31%) 0.6
SRSF2 mutated ‘N’ evaluable = 15 7 (47%) 1 (33%) 6 (54%) 0.5
Mayo Molecular Model risk categorization ‘N’ evaluable = 19
Low 2 (10%) 0 (0%) 2 (14%) 0.5
Intermediate-1 6 (32%) 1 (20%) 5 (36%) —
Intermediate-2 7 (37%) 2 (40%) 5 (36%) —
High 4 (21%) 2 (40%) 2 (14%) —
Mayo-French cytogenetic risk stratiﬁcation ‘N’ evaluable = 29
Low 22 (76%) 7 (78%) 14 (74%) 0.8
Intermediate 6 (21%) 2 (22%) 4 (21%) —
High 1 (3%) 0 (0%) 1 (5%) —
Median number of cycles (range) 6 (1–30) 4 (1–12) 7 (2–25) 0.4
Median duration of therapy in months (range) 5.0 (0.1–49) 4.2 (0.1–13) 5.0 (1.0–49) 0.1
Best response ‘N’ evaluable = 20
HI 2 (10%) 1 (14%) 1 (8%) —
PR 1 (5%) 0 (0%) 1 (8%) 0.3
CR 6 (32%) 1 (14%) 5 (38%) —
No response 11 (55%) 5 (71%) 6 (46%) —
Reason for discontinuation of therapy ‘n’ evaluable = 15
Progression 9 (60%) 2 (40%) 7 (70%) 0.03
Bridge to transplant 3 (20%) 3 (60%) 0 (0%) —
Death 3 (20%) 0 (0%) 3 (30%) —
Second HMA n (%) 2 (7%) 0 (0%) 2 (10%) —
Abbreviations: ASXL1, additional sex combs 1 gene; CMML, chronic myelomonocytic leukemia; CR, complete remission; HI, hematologic improvement; HMA,
hypomethylating agent; PR, partial remission; SRSF2, serine/arginine-rich splicing factor 2; WHO, World Health Organization. Bold entries signify statistically
signiﬁcant P-values (i.e. Po0.05).
CMML in younger patients
MM Patnaik et al
6
Blood Cancer Journal
DISCUSSION
CMML is uncommon in ‘young’ adults and is often associated with
signiﬁcant morbidity and mortality. Ours is the ﬁrst comprehen-
sive study evaluating presenting features, risk stratiﬁcation and
treatment outcomes in ‘young’ CMML patients, deﬁned by age
⩽ 65 years. The male predilection (73%), distribution across WHO
morphological sub-categories (CMML-1 84%) and presenting
laboratory features were similar to larger CMML studies analyzing
all age groups.2–4 Cytogenetic abnormalities were seen in 23% of
patients, with a lower frequency of +8 (16% versus 23%) and –Y
(14% versus 20%) in comparison to the Mayo-French cytogenetic
study cohort.5 On the other hand there was a higher frequency of
der(3q) (13% versus 8%) and − 7/del7q (18% versus 14%). None of
the patients with der(3q) had the classical t(3;3)(q21;q26) or inv3
(q21;q26), and ﬂuorescence in situ hybridization studies for EVI1
were negative. This abnormality (der(3q)) has been associated
with favorable outcomes in patients with CMML.5
ASXL1 mutations were seen in 33% of the patients (compared
with 39% and 40% in the Mayo Clinic and GFM studies,
respectively), while SRSF2 mutations were seen in 45% of the
patients (compared with 43% and 46% in the Mayo Clinic and
GFM studies, respectively).2,4 The median OS for CMML-1 and
CMML-2 were 59 months and 24 months, respectively (compared
with 38 months and 24 months in the combined Mayo-French
study of 466 patients).3 The risk designations based on the
Spanish cytogenetic risk stratiﬁcation, Mayo Prognostic model,
MDAPS and the MMM were similar, with the only exception being
that there were no ‘young’ patients with high risk GFM disease
stratiﬁcation, as age 465 years is considered an adverse
prognosticator in the GFM model.2
Contemporary prognostic models have identiﬁed anemia,
thrombocytopenia, circulating IMC, high WBC/AMC and ASXL1
mutations to be negatively prognostic for OS.2,3 In the current
study, platelet count, WBC/AMC and circulating IMC did not
impact OS. In addition to anemia and ASXL1 mutations, circulating
blast %, SRSF2 mutations and risk stratiﬁcation by the Mayo-
French cytogenetic classiﬁcation were independently prognostic.
SRSF2 mutations affect pre-messenger RNA splicing and have
been shown to exert a negative prognostic impact in myelodys-
plastic syndrome24 and primary myeloﬁbrosis,19 but not in
CMML.3,20 Their negative prognostic impact in ‘young’ adults with
CMML needs further elucidation. The LT rate in ‘young’ patients
was slightly higher at 28%, compared with 22% in the GFM study
and 17% in the Mayo-French study. Factors impacting LFS
Table 4. Clinical and laboratory features of 53 ‘young’ adults (age⩽ 65 years) with chronic myelomonocytic leukemia that underwent allogeneic
stem cell transplantation and their outcomes
Variables All N= 53 Myeloablative
conditioning
N=14 (33%)
Reduced intensity
conditioning
N=28 (67%)
P-value
Age 52 (18–65) 51 (27–62) 48 (18–65) 0.7
Sex 32 (60%) 8 (57%) 8 (57%) 1.0
WHO morphological subtype; n (%)
CMML-1 36 (68%) 8 (57%) 21 (75%) 0.2
CMML-2 17 (32%) 6 (43%) 7 (25%) —
ASXL1 ‘N’ evaluable = 25 7 (28%) 3 (33%) 1 (14%) 0.4
SRSF2 ‘N’ evaluable = 24 8 (33%) 4 (44%) 2 (29%) 0.5
Mayo-French cytogenetic risk stratiﬁcation — — — 0.7
Low 40 (75%) 11 (79%) 19 (68%) —
Intermediate 12 (23%) 3 (21%) 8 (29%) —
High 1 (2%) — 1 (3%) —
Mayo Molecular Model risk categorization ‘N’ evaluable = 25
Low 1 (4%) 0 (0%) 1 (14%) 0.5
Intermediate-1 8 (32%) 2 (22%) 1 (14%) —
Intermediate-2 5 (20%) 3 (33%) 1 (14%) —
High 11 (44%) 4 (44%) 4 (57%) —
Mayo-French cytogenetic risk stratiﬁcation ‘N’ evaluable = 53
Low 40(75%) 11 (79%) 19 (68%) 0.7
Intermediate 12 (23%) 3 (21%) 8 (29%) —
High 1 (2%) 0 (0%) 1 (3%) —
Graft source ‘N’ evaluable = 40
Matched sibling donor 20 (50%) 7 (54%) 12 (46%) 0.5
Matched unrelated donor 13 (32%) 4 (31%) 9 (35%) —
Mismatched unrelated donor 4 (10%) 1 (8%) 3 (11%) —
Umbilical cord blood units 1 (3%) 1 (8%) 0 (0%) —
Haploidentical donor 2 (5%) 0 (0%) 2 (8%) —
Acute GVHD ‘N’ evaluable = 40 19 (47%) 10 (76%) 9 (35%) 0.01
Chronic GVHD ‘N’ evaluable = 43 29 (67%) 8 (57%) 21 (75%) 0.2
Outcome of transplant ‘N’ evaluable = 43
CR 24 (56%) 8 (61%) 15 (55%) 0.4
Relapse 10 (23%) 1 (8%) 7 (26%) —
Death 8 (19%) 4 (31%) 4 (15%) —
Failure 1 (2%) 0 (0%) 1 (4%) —
Abbreviations: ASXL1, additional sex combs 1 gene; CMML, chronic myelomonocytic leukemia; CR, complete remission; GVHD, graft versus host disease;
SRSF2, serine/arginine-rich splicing factor 2; WHO, World Health Organization. Bold entries signify statistically signiﬁcant P-values (i.e. Po0.05).
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included circulating and BM blast% and the presence of IMC.
Notably, karyotypic risk designation, ASXL1 and SRSF2 mutations
did not impact LFS.
While prospective phase III data with HMA is lacking in CMML,
these agents are often used for the management of symptomatic
patients. Currently 5-AZA and DAC are approved for patients with
myelodysplastic syndrome in the USA, while in Europe DAC has
only been approved for elderly patients with de novo acute
myeloid leukemia, potentially explaining the higher number of
‘young’ patients who received 5-AZA (60%). In this study, patients
received a median of ﬁve cycles of 5-AZA and six cycles of DAC, for
a median duration of 5 months, with an over-all response rate of
40% for 5-AZA and 30% for DAC; once again similar to other
observational studies.6–12 Response prediction to HMA has been
challenging. Braun et al.8 demonstrated that ASXL1, NRAS, KRAS,
CBL, FLT3 and JAK2 mutations did not predict response or survival
in 39 CMML patients treated with DAC. However, lower CJUN and
CMYB gene expression levels independently predicted improved
OS. There was a trend toward higher response rate in patients
with TET2 mutations (when not associated with an ASXL1
mutation).8 Recently, in myelodysplastic syndrome, clonal TET2
mutations were shown to predict HMA responses (odds ratio 1.99,
P= 0.036), especially when they occurred independent of clonal
ASXL1 mutations.25 In our study, neither ASXL1 nor SRSF2
mutations predicted HMA response. In a smaller sub-set of
‘young’ French patients (n= 53), while there was a trend toward
better HMA responses in TET2 mutated patients (P= 0.5), this did
not reach statistical signiﬁcance.
AHSCT is the only potentially curative option, and is more likely
to be offered to ‘young’ adults with CMML. Eissa et al.13 reported
outcomes on 85 patients with CMML (median age 52 years) that
underwent AHSCT (32% RIC). After a median follow-up of 5.2 years
49 (58%) had died; 20 from disease relapse and 29 from non-
relapse causes. About 26% developed grade II–IV acute GVHD and
40% developed chronic GVHD. A multivariable model identiﬁed
increasing age, high SCT comorbidity index and poor risk
cytogenetics as independent prognosticators for poor survival. A
recent European study, evaluated AHSCT in 73 patients (median
age 53 years) with CMML (61% CMML-1, 43 RIC).26 The three year
OS was 32%, NRM 36% and the cumulative incidence of relapse
was 35%. Survival was not inﬂuenced by the CR status, BM blast%
at AHSCT, prior treatments and chronic GVHD. In our study, 53
(24%) patients underwent an AHSCT, with 67% receiving a RIC.
About 44% had high risk disease according to the MMM and 50%
received stem cells from a matched related donor. Alternative
donor sources used included: MUDs (32%), mismatched unrelated
donors (10%), double umbilical cord blood units (3%) and
haploidentical transplants (5%). Acute GVHD was seen in 47%,
while chronic GVHD was seen in 67% of patients. There was one
case of engraftment failure, involving a patient who received an
umbilical cord blood transplant. The response rate (CR) was
56%, NRM 19% and relapse rate 23%. Once again, ASXL1, SRSF2
mutational status and karyotype designations did not affect
transplant outcomes.
In summary, this is the largest study analyzing survival and
treatment outcomes in ‘young’ adults with CMML. Survival in
these patients, although higher than in older patients, is poor and
is even worse in the setting of ASXL1 and SRSF2 mutations. These
mutations, however, did not predict HMA response or impact
transplant outcomes, suggesting that these treatments could
erase the poor prognostic impact of these mutations in patients
receiving only supportive care.
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